Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy New Year, biotech ...

Meanwhile Steglujan (ertugliflozin+sitagliptin), a fixed dose combination combining the SGLT2 with Merck’s Januvia, is approved in type 2 disease when patients who need both drugs. Ertugliflozin ...

With a market cap of $252.6 billion, Rahway, New Jersey-based Merck & Co., Inc. (MRK) is a global leader in the healthcare ...

Merck, a leading global pharmaceutical company ... Some of the company’s key drugs include Keytruda, Januvia, Gardasil, and ProQuad. Keytruda, their triumphant cancer drug, is the company ...

Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, ...

Drug companies are also reducing some prices on Jan. 1. Merck & Co plans to cut the list price of its heavily discounted ...

Starting New Year’s Day, drugmakers were set to increase prices on at least 250 brand-name medications, according to data ...

More than 250 medications, including Paxlovid and cancer therapies, will see price increases in the United States beginning ...

Happy New Year, biotech friends! We’re back with news, including Merck’s decision to cut the price of its diabetes drug Januvia by 42% and Neumora’s readout on its experimental depression drug.

Happy New Year, biotech friends! We’re back with news, including Merck’s decision to cut the price of its diabetes drug Januvia by 42% and Neumora’s readout on its experimental depression drug.